

JC03 Rec'd PCT/PTO 29 APR 2005

PATENT Case No. 21204P

PCJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: I.E. KOPKA et al.

Serial No. 10/527,561

Filed: March 11, 2005

For: SUBSTITUTED PYRIMIDINES

Art Unit: \_\_\_\_\_

Examiner: \_\_\_\_\_

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR 1.97


Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By



Date

4/27/05

**INFORMATION DISCLOSURE STATEMENT**

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: CATHERINE D. FITCH

Attorney \_\_\_\_\_ For Applicant(s)

Reg. No. 36,502

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4283

Date: April 27, 2005

**COMPLETE IF KNOWN**

<b>Application Number</b>	10/527,561
<b>Filing Date</b>	March 11, 2005
<b>First Named Inventor</b>	I.E. Kopka et al.
<b>Group Art Unit</b>	
<b>Examiner Name</b>	

Attorney Docket Number	21204P
------------------------	--------

1

of

4

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
			EP 0 576 357		Sanofi	03/05/1997
			EP 0 656 354		Sanofi	06/04/1997
			WO 2004/111039		AstraZeneca AB	12/23/2004
			WO 2004/111033		AstraZeneca AB	12/23/2004
			WO 2004/111034		AstraZeneca AB	12/23/2004
			WO 2004/111038		AstraZeneca AB	12/23/2004
			WO 2005/000817		Sanofi-Aventis	01/06/2005
			WO 2004/037823		Pfizer Products Inc.	05/06/2004
			WO 2004/012671		Merck & Co., Inc.	02/12/2004
			WO 2004/110453		Pfizer Products Inc.	12/23/2004

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO:** Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

## STATEMENT BY APPLICANT

(use ~~is~~ many sheets as necessary)

.2

of

4

**Application Number**

10/527.561

**Filing Date**

March 11, 2005

**First Named Inventor**

I.E. Kopka et al.

Group Art Unit

Examiner Name

Attorney Docket Number

21204P

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
			WO 2005/020992		Solvay Pharmaceuticals GmbH	03/10/2005
			WO 2005/016286		Bristol-Myers Squibb Company	02/24/2005
			WO 2003/084943		Sanofi-Synthelabo	10/16/2003
			WO 03/027076		Solvay Pharmaceuticals B.V.	04/03/2003
			WO 2004/035566		Pfizer Products Inc.	04/29/2004
			WO 2004/094421		Pfizer Products Inc.	11/04/2004
			WO 03/051850		AstraZeneca AB/AstraZeneca UK Limited	06/26/2003
			WO 03/051851		AstraZeneca AB/AstraZeneca UK Limited	06/26/2003
			WO 2004/105699		Pharmacia Corporation	12/09/2004
			WO 2004/018433		Glaxo Group Limited	03/04/2004

**Examiner  
Signature**

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

4

**Application Number**

10/527,561

**Filing Date**

March 11, 2005

**First Named Inventor**

I.E. Kopka et al.

## Group Art Unit

Examiner Name

Attorney Docket Number

21204P

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
			WO 2004/052864	Pfizer Products Inc.	06/24/2004
			WO 98/37061	Bayer Aktiengesellschaft	08/27/1998
			WO 03/002114	AB Science	01/09/2003
			WO 03/006007	Research & Innovation Soc. Coop. A R.L.	01/23/2003
			WO 98/32441	Sanofi	07/30/1998
			WO 01/58450	Sanofi-Synthelabo	08/16/2001
			WO 2005/009479	Merck & Co., Inc.	02/03/2005
			WO 03/000787	The Nisshin Oil Mills, Ltd./Ina Food Industry Co., Ltd.	03/01/2003

Examiner  
Signature

Date  
Considered


\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**



(use many sheets as necessary)

**COMPLETE IF KNOWN**

Application Number	10/527,561
Filing Date	March 11, 2005
First Named Inventor	I.E. Kopka et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	21204P

Sheet	4	of	4
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Le Foll et al., J. Pharm. & Exper. Ther., Vol. 312 (2005), pp. 875-883, "Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence"
	AB	Lange et al., J. Med. Chem., pp. A-P, "Bioisosteric replacements of the pyrazole moiety of rimonabant ..."
	AC	Piomelli et al., Trends in Pharma. Sci., Vol. 21 (2000), pp. 218-224, "The endocannabinoid system as a target for therapeutic drugs"
	AD	Goya et al., Exp. Opin. Ther. Patents, Vol. 10 (2000), pp. 1529-1538, "Recent advances in cannabinoid receptor agonists and antagonists"
	AE	Xiang et al., Ann. Reports in Med. Chem., Vol. 34 (1999), pp. 199-208, "Chap. 20. Pharmacology of cannabinoid receptor agonists and antagonists"
	AF	Barth, Exp. Opin. Ther. Patents, Vol. 8 (1998), pp. 301-313, "Cannabinoid receptor agonists and antagonists"
	AG	Rinaldi-Carmona et al., Life Sciences, Vol. 56 (1995), pp. 1941-1947, "Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist"
	AH	Rinaldi-Carmona et al., FEBS Letters, Vol. 350 (1994), pp. 250-244, "SR141716A, a potent and selective antagonist of the brain cannabinoid receptor"
	AI	Hetzheim et al., Pharmazie, Vol. 40(1) (1985), pp. 17-20, "Ringtransformation von O,N-heterocyclen"

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003